Fecal markers: calprotectin and lactoferrin
- PMID: 22500530
- DOI: 10.1016/j.gtc.2012.01.007
Fecal markers: calprotectin and lactoferrin
Abstract
Overall, fecal markers have been found to be more accurate than serum markers. However, fecal markers are not specific for IBD and may be elevated in a range of organic conditions. Fecal calprotectin and lactoferrin can still differentiate inflammatory disease from functional bowel disorders. Comparison studies have found an overall diagnostic accuracy in IBD of 80% to 100% for both calprotectin and lactoferrin. Elevated levels are found in both CD and UC making it difficult to distinguish between these 2 diagnoses from these biomarkers alone. Both markers correlated well to mucosal healing and histologic improvement. Hence, they may be useful in monitoring response to treatment and predicting endoscopic and clinical relapse. Overall, patients with elevated markers were at higher risk of postoperative recurrence than those with normal levels. Fecal markers are useful in predicting pouchitis as well. Fecal markers are helpful as an adjunctive tool in overall evaluation of patients with nonspecific symptoms and as a management tool in those with inflammatory disease to monitor disease activity and possibility of relapse. They are less invasive than colonoscopy and can help guide management in a more cost-effective manner.
Similar articles
-
Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.Am J Gastroenterol. 2008 Jan;103(1):162-9. doi: 10.1111/j.1572-0241.2007.01556.x. Epub 2007 Oct 4. Am J Gastroenterol. 2008. PMID: 17916108
-
Accuracy of four fecal assays in the diagnosis of colitis.Dis Colon Rectum. 2007 Oct;50(10):1697-706. doi: 10.1007/s10350-007-0303-9. Dis Colon Rectum. 2007. PMID: 17762964 Clinical Trial.
-
Clinical utility of calprotectin and lactoferrin in patients with inflammatory bowel disease: is there something new from the literature?Expert Rev Clin Immunol. 2012 Aug;8(6):579-85. doi: 10.1586/eci.12.50. Expert Rev Clin Immunol. 2012. PMID: 22992152 Review.
-
Review of fecal biomarkers in inflammatory bowel disease.Dis Colon Rectum. 2008 Aug;51(8):1283-91. doi: 10.1007/s10350-008-9310-8. Epub 2008 Jun 10. Dis Colon Rectum. 2008. PMID: 18543035 Review.
-
Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome.Clin Lab. 2005;51(3-4):117-26. Clin Lab. 2005. PMID: 15819166
Cited by
-
Calprotectin could be a potential biomarker for acute appendicitis.J Transl Med. 2016 Apr 27;14(1):107. doi: 10.1186/s12967-016-0863-3. J Transl Med. 2016. PMID: 27118309 Free PMC article.
-
Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.Sci Rep. 2017 Jun 1;7(1):2669. doi: 10.1038/s41598-017-02835-5. Sci Rep. 2017. PMID: 28572616 Free PMC article.
-
Fecal biomarkers of intestinal health and disease in children.Front Pediatr. 2014 Jan 28;2:6. doi: 10.3389/fped.2014.00006. eCollection 2014. Front Pediatr. 2014. PMID: 24479111 Free PMC article. Review.
-
Novel Testing Enhances Irritable Bowel Syndrome Medical Management: The IMMINENT Study.Glob Adv Health Med. 2014 May;3(3):25-32. doi: 10.7453/gahmj.2013.100. Glob Adv Health Med. 2014. PMID: 24891991 Free PMC article.
-
Fecal calprotectin: its scope and utility in the management of inflammatory bowel disease.J Gastroenterol. 2016 May;51(5):434-46. doi: 10.1007/s00535-016-1182-4. Epub 2016 Feb 20. J Gastroenterol. 2016. PMID: 26897740 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical